Lidocaine Wound Gel, 0.13% recall — Water-jel Technologies, LLC (Class III)
Water-jel Technologies, LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%) — a Class III recall, initiated 2026-04-07 and posted to the FDA enforcement report on 2026-05-06, under recall number D-0509-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Failed PH Specifications”. From the product description, the form is gel and the strengths given are 0.13%, 2% and 14 g. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in NC, United States. It is the only recall number the FDA has filed under event ID 98737. 29 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0509-2026 |
|---|---|
| FDA event ID | 98737 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Water-jel Technologies, LLC |
| Recall initiated | 2026-04-07 |
| Reported by FDA | 2026-05-06 |
| Report lag | 29 days from initiation to report |
| Distribution | Nationwide in the USA — Nationwide (US) |
| Firm location on record | NC, United States |
| Product description (source) | Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%), NET WT 0.5 OZ (14 g), Distributed by: CVS PHarmacy, INc., One CVS Drive, Woonsocket, RI 02895. NDC 59898-950 |
Reason reported by FDA
Failed PH Specifications
3 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
5 identifying values matched by exact pattern in the 29-word product description above; each is a literal substring of it.
| Product named | Lidocaine Wound Gel (Benzalkonium Chloride, 0.13% and Lidocaine Hydrochloride, 2%) |
|---|---|
| Form | Gel |
| Strength | 0.13% · 2% · 14 g |
| Distributed by | CVS PHarmacy, INc. |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Levocarnitine Injection, 1 g/5 mL | D-0494-2026 | American Regent, Inc. | Class III | 2026-05-06 |
| busPIRone Hydrochloride Tablets, 5 mg | D-0511-2026 | Unichem Pharmaceuticals Usa Inc. | Class III | 2026-05-13 |
| Primidone Tablets USP, 250mg | D-0533-2026 | Lannett Company Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 50 mg | D-0534-2026 | Golden State Medical Supply Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0535-2026 | Golden State Medical Supply Inc. | Class III | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0536-2026 | Amerisource Health Services LLC | Class III | 2026-05-27 |
| Primidone Tablets, 50 mg | D-0537-2026 | Amerisource Health Services LLC | Class III | 2026-05-27 |
| Busulfan Injection, 60 mg | D-0539-2026 | Sagent Pharmaceuticals | Class III | 2026-05-27 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 8 nearest to 2026-05-06 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Premier, 8 mL | D-0490-2026 | Premier Dental Products Co | 8 mL · Solution | 2026-04-29 |
| Nicotine Transdermal System Patch, 14 mg | D-0550-2026 | Aveva Drug Delivery Systems, Inc. | 14 mg · Transdermal System | 2026-06-03 |
| PRED MILD, 0.12% | D-0551-2026 | Abbvie Inc. | 0.12% · Ophthalmic Suspension | 2026-06-03 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL | D-0619-2026 | Ani Pharmaceuticals, Inc. | 10 mg/5 mL · Oral Solution | 2026-07-01 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Water-jel Technologies, LLC (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0509-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0509-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-06
- Ingested
- 2026-08-22
- Record hash
d81300aa9a545c56
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.